The strong Phase III data and dual priority review status for wAIHA and ITP NDAs significantly de-risk sovleplenib's regulatory path in China. Monitor NMPA approval decisions and potential label expansion globally, as HUTCHMED retains worldwide rights.
HCM drugs
HCM drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $10.96entry
- T+1 · 5mo ago −1.19%α −2.95% · $10.83
- T+5 · 5mo ago −6.20%α −6.88% · $10.28
- T+20 · 4mo ago +1.00%α −0.78% · $11.07
- T+60 · 2mo ago +26.64%α +23.38% · $13.88
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED presented Phase III ESLIM-02 data for sovleplenib in wAIHA at EHA 2026, showing a 66% durable response rate vs 15% placebo (p<0.0001) with a favorable safety profile. The NDA for wAIHA was accepted with priority review by China's NMPA in April 2026, and a resubmitted NDA for ITP also received priority review in February 2026. These regulatory milestones and strong efficacy data de-risk the pipeline for a second indication beyond ITP, though no revenue or earnings figures are disclosed.
Key Facts
- Phase III ESLIM-02 met primary endpoint: durable response rate 66% sovleplenib vs 15% placebo (p<0.0001)
- Overall response rate 70% vs 22% (p<0.0001); rescue therapy use reduced to 16% vs 54% (p=0.0001)
- NDA for wAIHA accepted with priority review by NMPA in April 2026; Breakthrough Therapy Designation granted March 2026
- Resubmitted NDA for ITP also granted priority review by NMPA in February 2026
- No TEAE-related deaths or treatment discontinuations in sovleplenib arm; Grade 3 TEAEs 43% vs 59% placebo
- HUTCHMED retains all worldwide rights to sovleplenib
Financial Impact
No revenue or financial figures disclosed; potential peak sales for sovleplenib in wAIHA and ITP in China are not quantified in the filing
Risk Factors
- Regulatory approval in China is not guaranteed despite priority review
- Commercial adoption depends on pricing, reimbursement, and competition from existing steroids and rituximab
- Global expansion outside China would require additional clinical trials and regulatory submissions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000039 |
| Document: hcm-20260612x6k.htm | 0001648257-26-000039 |
| Document: 0001648257-26-000039-index-headers.html | 0001648257-26-000039 |
| Document: 0001648257-26-000039-index.html | 0001648257-26-000039 |
| Document: 0001648257-26-000039.txt | 0001648257-26-000039 |
Track record
33 reports on HCM
7 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers